Topic: FDA expanded access

A daily pill nearly doubled survival for patients with stage 4 pancreatic cancer in a landmark trial, and US hospitals have begun offering it ahead of FDA approval. Patients on daraxonrasib lived a median of 13.2 months, compared with 6.7 months on standard intravenous chemotherapy.